Abstract
The BCl-2 family has long been identified for its role in apoptosis. Following the initial discovery of BCL-2 in the context of B-cell lymphoma in the 1980s, a number of homologous proteins have since been identified. The members of the Bcl-2 family are designated as such due to their BCL-2 homology (BH) domains and involvement in apoptosis regulation. The BH domains facilitate the family members’ interactions with each other and can indicate pro- or anti-apoptotic function. Traditionally, these proteins are categorised into one of the three subfamilies; anti-apoptotic, BH3-only (pro-apoptotic), and pore-forming or ‘executioner’ (pro-apoptotic) proteins. Each of the BH3-only or anti-apoptotic proteins has a distinct pattern of activation, localisation and response to cell death or survival stimuli. All of these can vary across cell or stress types, or developmental stage, and this can cause the delineation of the roles of BCL-2 family members. Added to this complexity is the presence of relatively uncharacterised isoforms of many of the BCL-2 family members. There is a gap in our knowledge regarding the function of BCL-2 family isoforms. BH domain status is not always predictive or indicative of protein function, and several other important sequences, which can contribute to apoptotic activity have been identified. While therapeutic strategies targeting the BCL-2 family are constantly under development, it is imperative that we understand the molecules, which we are attempting to target. This review, discusses our current knowledge of anti-apoptotic BCL-2 family isoforms. With significant improvements in the potential for splicing therapies, it is important that we begin to understand the distinctions of the BCL-2 family, not limited to just the mechanisms of apoptosis control, but in their roles outside of apoptosis.
Similar content being viewed by others
Facts
-
BCL-2 family members play an integral role in apoptosis, but also contribute to many other cellular functions.
-
Isoforms of almost all of the BCL-2 family members have been identified and some are well characterised.
-
Therapeutics targeting BCL-2 show great promise for the treatment of cancer.
Open questions
-
What is the functional role of uncharacterised BCL-2 family member isoforms in apoptosis and normal cellular functions, in particular the BCL-2 isoform BCL-2β?
-
Is the presence and varied functional characteristics of BCL-2 family isoforms being considered in the development of therapeutics targeting BCL-2?
-
Is there potential to target BCL-2 family member isoforms that are expressed higher in cancer?
Introduction
The BCl-2 family has long been identified for its role in apoptosis. Following the initial discovery of BCL-2 in the context of B-cell lymphoma in the 1980s, a number of homologous proteins have since been identified1,2,3. The members of the Bcl-2 family are designated as such due to their BCL-2 homology (BH) domains and involvement in apoptosis regulation. The BH domains facilitate the family members’ interactions with each other, and can indicate pro- or anti-apoptotic function4,5. Traditionally, these proteins are categorised into one of three subfamilies; anti-apoptotic, BH3-only (pro-apoptotic), and pore-forming or ‘executioner’ (pro-apoptotic) proteins. Subfamily categorization has been traditionally based on BH and transmembrane domain and anti- or pro-apoptotic function status, as well as pore-forming ability (as shown in Table 1).
The role of the BCL-2 family in apoptotic regulation is typically described as the anti-apoptotic and pro-apoptotic BH3-only members existing in a state of competitive flux to influence the activation of the pore-forming executioners6,7. The ratio of pro- to anti-apoptotic subfamily members present in a cell can be altered by a number of signalling pathways, effectively relaying information on cellular stress, such as available nutrients, DNA damage, and protein processing8. Once the executioners are activated, the molecules come together to form pores in the outer mitochondrial membrane (MOM) and thus trigger mitochondrial outer membrane permeability (MOMP), and therefore apoptosis9,10,11.
The BH domains are considered central to subfamily categorization as they facilitate the interaction of family members. BH3 was initially highlighted as an important domain as it was demonstrated to be vital for the interaction of the anti-apoptotic BCL-XL and the executioner BAK, as well as for its apoptotic activity. The BH3 domain is vital for the correct folding of a hydrophobic pocket, within which BCL-2 members can interact12,13. Consequently, point mutations or deletions of the BH3 domain have been shown to significantly reduce the pro-apoptotic activity of a number of BH3-only proteins14. The BH4 domain is thought to be similarly significant for the anti-apoptotic subfamily; deletion of the BH4 domain can switch function to pro-apoptotic, while retention of the BH4 domain alone is sufficient to block changes in mitochondrial potential14.
Beyond this understanding of a competitive flux, there are several hypotheses regarding how the BCL-2 family members interact, including direct and indirect interactions amongst family members (summarised in Supplementary Table 1). Each of the BH3-only or anti-apoptotic proteins have patterns of activation, localisation and response to specific death or survival stimuli. Binding selectivity between members of the different classes of BCL2 proteins also varies, for example, some BH3-only proteins bind non-specifically to several BCL2 prosurvival proteins while others tend to bind in a more specific manner. Similarly, BCL2 prosurvival family members can selectively bind to and limit activity of BAX or BAK. All of these interactions can vary across cell or stress types, or developmental stage, and this can cause the delineation of the roles of BCL-2 family members. Added to this complexity is the presence of relatively uncharacterised isoforms of many of the BCL-2 family members.
BCL-2 anti-apoptotic subfamily
This review focuses on the BCL-2 anti-apoptotic subfamily and known isoforms. Traditionally, members of this family are identified by their anti-apoptotic activity as well as the presence of BH4 and transmembrane domains for anchoring to cellular membranes15. Some members of this anti-apoptotic subfamily lack some of these physical features, have isoforms translated from the same gene which actually have pro-apoptotic activity, or can have their activity modulated by post-translational modification, as reviewed below and summarised in Table 2.
BCL-X
The BCL-X or BCL2L1 (BCL2-like 1) gene has 44% homology to BCL-2. It has two well-known isoforms, BCL-XL and BCL-XS (Table 2), as well as a number of other characterised isoforms16,17. The two major isoforms arise from alternative splicing of BCL-X; splicing at the distal end of the 5′ splice site within the first coding exon for production of BCL-XL and at the proximal end for BCL-XS. Interestingly, the two isoforms have a different role in apoptosis. While BCL-XL is anti-apoptotic, BCL-XS is pro-apoptotic. Overexpression of BCL-XL, but not BCL-XS, confers survival in IL-3-dependent cells following IL-3 deprivation18. Transfection of these IL-3-dependent cells with BCL-XS reinstates their sensitivity to IL-3 removal, regardless of levels of anti-apoptotic BCL-219. This protective effect has been seen in several cell types, in response to chemotherapeutic drug treatment and growth factor removal20.
The BCL-XL protein is comprised of seven alpha-helices, where the two central hydrophobic helices (α5 and α6) are surrounded by five amphipathic helices (α3, α6, α1, α2, and α7). The BH1, BH2, and BH3 domains sit in close proximity, and form a hydrophobic cleft for binding other family members. The C-terminal transmembrane domain extends from the α7 helix. The N-terminal helix (α1) is essential for maintenance of structure stabilisation as it forms extensive interactions with the other helices. The BH3 domain is contained within the α2 helix, the BH1 domain across the α4 and α5, and BH2 across α6 and α721.
The protein structure of BCL-XS has not been comprehensively described, but the loss of both BH1 and BH2 domains would significantly alter the hydrophobic binding cleft22. While BCL-XL exerts its anti-apoptotic regulation by formation of heterodimers with both BAX and BAK, the pro-apoptotic function of BCL-XS is derived from its capacity to disrupt the BAK/VDAC complex through its interaction with voltage-dependent anion channel (VDAC), thus freeing BAK for activation23. This highlights the difference in binding capacity between the two isoforms.
Since this discovery of the alternate functions of the two variants, the mechanisms of splicing control of the BCL-X gene have been a matter of some interest. It has been demonstrated that switching of splicing favour is induced by cellular stress, specifically DNA damage24,25, protein synthesis stalling26, and protein kinase C inhibition27,28. The induction of generic cellular stress via treatment with the drug ceramide as well as the combination of epigallocatechin-3-gallate (EGCG) and non-steroidal anti-inflammatory (ibuprofen) have also been shown to shift splice favour29,30.
Immunoprecipitation assays on known regulatory regions have identified proteins essential to BCL-X splice control, such as HNRNPK and PTBP131,32. In addition, investigation of known pro-apoptotic transcription factor targets (SC35 via E2F1)25, RNA binding proteins (SAM68, SAP155)33,34, splice modulators (hnRNP F/H, SRp30c, RBm25, Akt SUMO, TCERG1)35,36,37,38,39, and pathways demonstrated to shift Bcl-Xs splicing favour (SB1 and RBM25)24,37, have identified a number of other spliceosomal and RNA binding proteins which are involved in BCL-X splicing regulation. As well as these proteins, a lncRNA, RNA INXS, transcribed from the opposite strand of BCL-X, and proto-oncogenes FBI-1 and FYN, are capable of modulating SAM68 activity in favour of BCL-XS splicing40,41.
BCL-XL is also known to be involved in calcium signalling regulation via IP3R and VDAC142,43, can regulate Ca2+ homeostasis when localised at the endoplasmic reticulum44 and reduce mitochondrial Ca2+ uptake45. The RNA-binding protein HuR, a translational repressor of BCL-XL, can also affect maintenance of mitochondrial morphology, which regulates cellular apoptosis, through translational control of BCL-XL expression46. BCL-XL has been linked to non-apoptotic cell death by binding the tumour suppressor Beclin 1, subsequently inhibiting autophagy47. The overexpression of BCL-XL has been shown to protect endothelial cells from TNF-mediated apoptosis and is involved in inflammatory response by inhibiting the activation of NF-κB and thus the upregulation of proinflammatory genes48. Interestingly, BCL-XL has also been shown to have apoptosis-independent function in metastasis in pancreatic neuroendocrine tumour and breast cancer cell lines via nuclear promotion of epithelial–mesenchymal transition, migration, invasion and stemness49 and in chemoresistance via RAS interaction and influence on EMT and regulation of cancer-initiating cell (CICs)50.
Interestingly, despite the mass of research conducted on BCL-XL and BCL-X splicing control, there is relatively little known about BCL-XS. It is a BAK-dependent pro-apoptotic protein23,51,52, but any roles outside of apoptosis regulation have not yet been identified. Induction of an increased ratio of BCL-XS to BCL-XL or overexpression of BCL-XS in cancer cell lines have been shown to have a pro-apoptotic effect20,53,54,55.
MCL-1
MCL-1 (myeloid leukemia sequence 1) was initially discovered due to its upregulation in the MC-1 hematopoietic cell line during the differentiation from monocyte to macrophage56. At the time of discovery, the MCL-1L transcript was the only known transcript, and it was rapidly designated as anti-apoptotic after overexpression was observed to protect cells from heat shock57. However, there are now three known isoforms of the gene; MCL-1L, MCl-1S and MCL-1ES (Table 2). Similar to the BCL-X isoforms, the three proteins have different roles in the regulation of apoptosis; MCL-1L is anti-apoptotic, while MCL-1S and MCL-1ES are both pro-apoptotic58,59.
The C-terminal domain of MCL-1L is 350 amino acids long and has sequence homology with BCL-2. A central hydrophobic helix (α5) is surrounded by a set of amphipathic helices, which pack tightly against it (α1, α2, α3, α4, α5, α6, α7), where α3 and α4 are less densely packed, and BH1 is contained within α5 and α6. Helices α2, α3 and α4 form the characteristic hydrophobic binding groove and contain the BH3 domain, where α5 and α8 form the base of the groove60. MCL-1L also harbours a C-terminal transmembrane domain58,60. Unlike other members of the BCL-2 family, the MCL-1L N-terminus contains a PEST sequence that is associated with rapidly degrading proteins, as well as multiple sites for phosphorylation and caspase cleavage sequences61. These post-translational modifications can change protein stability and function, and consequently, MCL-1L has a high rate of turnover within the cell and its degradation can be modulated at several points along the N-terminus58,62.
Alternatively, skipping of the second exon of the MCL-1 gene gives rise to the 271 amino acid MCL-1S (Table 2). This variant retains the BH3, BH4 and PEST domains, but not the BH1, BH2 and transmembrane domains. This gives rise to an isoform with features characteristic of a BH3-only protein, in which heterodimerization with anti-apoptotic MCL-1L can block its pro-apoptotic activity. In addition, MCL-1S is incapable of binding with BAX, BAK and BIM, whereas BCL-XL interacts strongly with these family members58. Besides this initial study that described the key features of MCL-1S, there is relatively little known about the protein.
A third isoform, MCL-1ES, has also been identified. MCL-1ES occurs as a result of alternative splicing within the first exon at a non-canonical donor-acceptor site. The resultant protein is 197 amino acids long and lacks the PEST sequence and BH4 domain present in the other MCL-1 isoforms (Table 2). This isoform displays a pro-apoptotic function, with overexpression of this isoform resulting in decreased resting cell viability and mitochondrial integrity, all leading to cell death59. Interestingly, the effects are amplified when MCL-1ES is co-transfected with MCL-1L, an anti-apoptotic family member59. Further work has demonstrated that MCL-1ES localisation to the mitochondria and consequent pro-apoptotic activity is dependent on its heterodimerization with MCL-1L59,63. Interestingly, the effect of overexpression on apoptosis is BAX/BAK-dependent, and preliminary studies indicate that MCL-1ES can form the mitochondrial pores for the initiation of apoptosis by the release of cytochrome c and activation of MOMP. This activity is dependent on the BH3 domain of MCL-1ES63.
Although studies have been performed on splicing control between MCL-1L and MCL-1S, the mechanisms of MCL-1ES splicing control are still unknown. Much of the work in delineating MCL-1 splicing regulators was performed in parallel with BCL-X investigations. For example, treatment of prostate cancer cell lines with EGCG/ibuprofen switched splicing favour to the pro-apoptotic variant for both MCL-1 and BCL-X in a protein phosphatase 1 (PP1)-dependent manner30. In addition, a study by Moore et al. (2010) identified that the splicing regulator ASF/SF2, and protein kinases PLK1 and WEE1, can shift splicing in favour of MCL-1S64. The same study identified SAP155 as a driver for transcription of pro-apoptotic splice variants for both MCL-1 and BCL-X, and this result has since been validated by other studies64,65. These data indicate that MCL-1 splicing regulation is associated with cell cycle control.
Of the three isoforms, only MCL-1L has been found to have roles outside of apoptosis. Like BCL-2 and BCL-XL, MCL-1L can regulate autophagy, mitochondrial morphology, and calcium signalling via its interaction with IP3R66, and is involved in cell cycle control61 and lipid metabolism67.
BCL-2
BCL-2 was the first member of the family to be identified, due to its role in B-cell lymphoma. A chromosomal translocation between chromosomes 14 and 18 in this disease, t(14:18), causes enhancement of BCL-2 transcription, which confers a survival advantage to the cancerous cells1,2,3. The BCL-2 gene is comprised of three exons; the first two exons encode the four BH domains, whereas the exon 3 encodes the transmembrane domain that anchors the protein to intracellular membranes68,69 (Fig. 1). There are two isoforms of BCL-2; BCL-2α and BCL-2β. While BCL-2α is anti-apoptotic3,70,71,72, BCL-2β is yet to be fully characterised. It lacks exon 3 and thus the transmembrane-anchoring domain, but otherwise shares the same BH domains and general structure of BCL-2α (Fig. 1). BCL-2β also has an isoform-specific 9-amino acid stretch at its C-terminal domain73 (Table 2).
Roles of BCL-2α
The structure of the BCL-2α protein is similar to BCL-XL, with two central hydrophobic helices (α1 and α2) surrounded by five α-helices, and a C-terminal transmembrane domain. Like BCL-XL, this characteristic hydrophobic groove is comprised of helices 3, 4, 5 and 6. The structure of the BCL-2β protein is yet to be ascertained, but is known to lack the transmembrane domain, although the significance of this is unclear. While several studies have concluded that a C-truncated BCL-2α is incapable of localising to appropriate organelles, bind target proteins or regulate apoptosis74,75,76,77,78, others have disputed the significance of a transmembrane domain79,80,81. However, it is important to note that all these studies have been performed on truncated BCL-2α but not on wildtype BCL-2β.
BCL-2α binds to BAX via its BH1 and BH2 domains, and this interaction is central to its role in apoptosis regulation, as demonstrated in cell lines in response to cellular stress5. However, in several models of stress, such as gamma irradiation, IL-3 deprivation of dependent cells, glucocorticoid and cytotoxic drug treatment, and heat shock, it has been shown that, where BCL-2 is upregulated and capable of binding BAX, the capacity of cells to undergo apoptosis is reduced3,70,71,72. These investigations have emphasised the significance of the BH domains.
Like MCL-1L and BCL-XL, BCL-2α is the most extensively studied isoform and is involved in autophagy via interaction with Beclin 1, as well as calcium signalling, and has roles outside of apoptosis regulation82,83. Interestingly, the interaction between BCL-2 and Beclin 1 occurs at the same site as BH3-only proteins and so competition for the site exists between these proteins84. It has also been implicated in DNA repair, including nucleotide excision repair, base excision repair, mismatch repair and double-strand break repair82,85,86,87. In addition, BCL-2α can regulate a number of major transcription factors, including p5388, NF-κB, AP1, CRE and NFAT77. The different roles of BCL-2α are summarised in Table 3.
Current evidence for a role of BCL2β
Despite the accumulation of evidence for the many roles of BCL-2α, there has been very little investigation into the role of BCL-2β. Functional protein studies on BCL-2 primarily focuses on the wildtype BCL-2α. Where the BCL-2β isoform is addressed, a recombinant version of a C-terminal-truncated BCL-2α is used for characterisation studies and it has been assumed this structure shares the same function as BCL-2β, as both lack the transmembrane domain73. Characterisation studies on the BCL-2β isoform have so far been limited to cloned versions of the genes, which do not accurately reflect the naturally-occurring sequence74,76,78,89.
Studies that have assessed the significance of the transmembrane domain on the capacity for BCL-2 to regulate apoptosis and p53 and to interact with BAX and BRCA1 concluded that the domain was vital for the efficiency of BCL-2 in these roles74,76,78,90. In contrast, studies that have concluded that the transmembrane domain is not essential for function were focused on the separate steps of apoptosis activation and/or apoptosis across different cell types79,80. Despite these inconsistencies in the literature, it is important to note that C-terminal-truncated BCL-2α does not accurately represent BCL-2β, due to the isoform’s specific 9-amino acid C-terminal sequence (see Fig. 2).
Targeting the BCL2 family for therapeutic purposes
As the BCL-X and BCL-2 families have essential roles in apoptotic regulation and were initially discovered in the cancer setting, they have garnered interest as therapeutic targets. Several studies have tried to regulate apoptosis using retroviral systems91, alteration of localisation apparatus92, activity-blocking antibodies93, RNAi94 and miRNAs95. However, the most successful method so far for targeting the BCL-2 family has been through BH3-mimetic molecules.
BH3-mimetics
Initial proof-of-concept studies that highlighted the potential of BH3-mimetics showed that small molecules which bound to the hydrophobic groove of BCL-XL could block anti-apoptotic function96. Since then, many different BH3-mimetics have been developed, and these are summarized in Table 4.
Several studies have highlighted the significance of low MCL1 expression conferring sensitivity to BH3-mimetics in cell lines97,98. MCL-1L is one of the most potent of the BCL-2 family as it has a significantly high affinity with pro-apoptotic members. Several molecules with the potential for binding MCL-1L have been developed, A-1210477 was an early molecule proposed to act directly on MCL-1L to promote apoptosis in cell lines99,100. More recently, S63845 a small molecule that binds with high affinity to the BH3-binding groove of MCL1 has been shown to kill MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells101.
Manipulation of splicing
Splicing alters the function of BCL-2 members, therefore there is potential to target this therapeutically by manipulation of gene splicing to favour pro-apoptotic transcripts. Introduction of splicing-switching oligonucleotides that alter BCL-X splicing from BCL-XL to the pro-apoptotic BCL-XS in melanoma cell culture and tumour xenografts was shown to reduce tumour load102. Additionally, the transcription factor FBI-1 has been shown to have a role in alternative splicing by interacting with splicing factor SAM68, thus reducing binding of SAM68 to BCL-X and resulting in the preferential splicing of anti-apoptotic BCL-XL41. The silencing of FBI-1 expression restores the ability of SAM68 to induce splicing of pro-apoptotic BCL-XS41.
Another way to manipulate splicing is by targeting SAP155, a splicing factor which acts on MCL-1 and BCL-X. Inhibition of this protein by meaymycin B, and potent inhibitor of SAP155, has been used to switch splicing in favour of pro-apoptotic MCL-1s in cell culture65. Interestingly, the combination of meaymycin B with BH3-mimetic ABT-737 also induces apoptosis65. The activity of SAP155 has also been successfully downregulated using an anti-SAP155 antibody, which induced an increase in the pro-apoptotic BCL-XS isoform compared to BCL-XL, and this method can be used to prime the cell for response to apoptosis-inducing treatment33.
Targeting splicing factors to favour the expression of pro-apoptosis isoforms is appealing but the non-specific nature of splicing factors will need to be addressed for this to be a superior target than BH3 mimetics. A more targeted approach to manipulating splicing is the use of specific antisense oligonucleotides. Antisense oligonucleotides designed to knock-down exon 2 in MCL-1 pre-mRNA can shift splicing pattern from MCL-1L to MCL-1S103. This increases the expression of pro-apoptotic MCL-1S and reduces the level of anti-apoptotic MCL-1L, and was shown to induce apoptosis in basal cell carcinoma and gastric adenocarcinoma cell lines103. Manipulation of splicing remains an area of interest that requires further development to be a targeted as a treatment with clinical potential.
Summary
The BCL-2 family is involved in the regulation of apoptosis and therefore plays a vital role in protecting against cancer. Targeting the apoptotic pathway directly is a valid option for improving or developing new chemotherapies, but it is imperative that we understand the molecules, which we are attempting to modify, manipulate or mimic. As demonstrated in this review, there are gaps in knowledge regarding isoforms of anti-apoptotic BCL-2 family isoforms. Further studies focusing on understanding the variety of splice variants and isoforms and their biological role in apoptosis is required for targets of this pathway to reach their full potential.
References
Tsujimoto, Y. et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226, 1097–1099 (1984).
Tsujimoto, Y. et al. Involvement of the bcl-2 gene in human follicular lymphoma. Science 228, 1440–1443 (1985).
Tsujimoto, Y. Stress-resistance conferred by high level of bcl-2 alpha protein in human B lymphoblastoid cell. Oncogene 4, 1331–1336 (1989).
Petros, A. M. et al. Solution structure of the antiapoptotic protein bcl-2. Proc. Natl Acad. Sci. USA 98, 3012–3017 (2001).
Yin, X. M., Oltvai, Z. N. & Korsmeyer, S. J. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369, 321–323 (1994).
Certo, M. et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 9, 351–365 (2006).
van Delft, M. F. & Huang, D. C. How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res. 16, 203–213 (2006).
Hetz, C. & Glimcher, L. The daily job of night killers: alternative roles of the BCL-2 family in organelle physiology. Trends Cell Biol. 18, 38–44 (2008).
Nechushtan, A. et al. Bax and Bak coalesce into novel mitochondria-associated clusters during apoptosis. J. Cell Biol. 153, 1265–1276 (2001).
Chipuk, J. E. et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303, 1010–1014 (2004).
Martinou, J. C. & Green, D. R. Breaking the mitochondrial barrier. Nat. Rev. Mol. Cell Biol. 2, 63–67 (2001).
Petros, A. M., Olejniczak, E. T. & Fesik, S. W. Structural biology of the Bcl-2 family of proteins. Biochim. Biophys. Acta 1644, 83–94 (2004).
Shamas-Din, A. et al. BH3-only proteins: orchestrators of apoptosis. Biochim. Biophys. Acta 1813, 508–520 (2011).
Hossini, A. M. & Eberle, J. Apoptosis induction by Bcl-2 proteins independent of the BH3 domain. Biochem. Pharmacol. 76, 1612–1619 (2008).
Alberts, B., Molecular Biology of the Cell: Reference Edition (Taylor & Francis, New York, NY, USA 2008).
Hossini, A. M. et al. A novel Bcl-x splice product, Bcl-xAK, triggers apoptosis in human melanoma cells without BH3 domain. Oncogene 25, 2160–2169 (2006).
Ban, J. et al. Identification of a human cDNA encoding a novel Bcl-x isoform. Biochem. Biophys. Res. Commun. 248, 147–152 (1998).
Vaux, D. L., Cory, S. & Adams, J. M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335, 440–442 (1988).
Boise, L. H. et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74, 597–608 (1993).
Minn, A. J., Boise, L. H. & Thompson, C. B. Bcl-x(S) anatagonizes the protective effects of Bcl-x(L). J. Biol. Chem. 271, 6306–6312 (1996).
Muchmore, S. W. et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381, 335–341 (1996).
Chang, B. S. et al. The BH3 domain of Bcl-x(S) is required for inhibition of the antiapoptotic function of Bcl-x(L). Mol. Cell. Biol. 19, 6673–6681 (1999).
Plotz, M. et al. Disruption of the VDAC2-Bak interaction by Bcl-x(S) mediates efficient induction of apoptosis in melanoma cells. Cell Death Differ. 19, 1928–1938 (2012).
Shkreta, L. et al. The DNA damage response pathway regulates the alternative splicing of the apoptotic mediator Bcl-x. J. Biol. Chem. 286, 331–340 (2011).
Merdzhanova, G. et al. E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35. Cell Death Differ. 15, 1815–1823 (2008).
Boon-Unge, K. et al. Emetine regulates the alternative splicing of Bcl-x through a protein phosphatase 1-dependent mechanism. Chem. Biol. 14, 1386–1392 (2007).
Revil, T. et al. Protein kinase C-dependent control of Bcl-x alternative splicing. Mol. Cell. Biol. 27, 8431–8441 (2007).
Li, C. Y. et al. Regulation of alternative splicing of Bcl-x by IL-6, GM-CSF and TPA. Cell Res. 14, 473–479 (2004).
Massiello, A. et al. Identification of two RNA cis-elements that function to regulate the 5’ splice site selection of Bcl-x pre-mRNA in response to ceramide. J. Biol. Chem. 279, 15799–15804 (2004).
Kim, M. H. Protein phosphatase 1 activation and alternative splicing of Bcl-X and Mcl-1 by EGCG + ibuprofen. J. Cell. Biochem. 104, 1491–1499 (2008).
Bielli, P. et al. Regulation of BCL-X splicing reveals a role for the polypyrimidine tract binding protein (PTBP1/hnRNP I) in alternative 5’ splice site selection. Nucleic Acids Res. 42, 12070–12081 (2014).
Revil, T. et al. Heterogeneous nuclear ribonucleoprotein K represses the production of pro-apoptotic Bcl-xS splice isoform. J. Biol. Chem. 284, 21458–21467 (2009).
Massiello, A., Roesser, J. R. & Chalfant, C. E. SAP155 Binds to ceramide-responsive RNA cis-element 1 and regulates the alternative 5’ splice site selection of Bcl-x pre-mRNA. FASEB J. 20, 1680–1682 (2006).
Paronetto, M. P. et al. The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x. J. Cell Biol. 176, 929–939 (2007).
Garneau, D. et al. Heterogeneous nuclear ribonucleoprotein F/H proteins modulate the alternative splicing of the apoptotic mediator Bcl-x. J. Biol. Chem. 280, 22641–22650 (2005).
Cloutier, P. et al. Antagonistic effects of the SRp30c protein and cryptic 5’ splice sites on the alternative splicing of the apoptotic regulator Bcl-x. J. Biol. Chem. 283, 21315–21324 (2008).
Zhou, A. et al. Novel splicing factor RBM25 modulates Bcl-x pre-mRNA 5’ splice site selection. Mol. Cell. Biol. 28, 5924–5936 (2008).
Risso, G. et al. Modification of Akt by SUMO conjugation regulates alternative splicing and cell cycle. Cell Cycle 12, 3165–3174 (2013).
Montes, M. et al. TCERG1 regulates alternative splicing of the Bcl-x gene by modulating the rate of RNA polymerase II transcription. Mol. Cell. Biol. 32, 751–762 (2012).
DeOcesano-Pereira, C. et al. Long non-coding RNA INXS is a critical mediator of BCL-XS induced apoptosis. Nucleic Acids Res. 42, 8343–8355 (2014).
Bielli, P., et al., The transcription factor FBI-1 inhibits SAM68-mediated BCL-X alternative splicing and apoptosis. EMBO reports, 419–427 (2014).
White, C. et al. The endoplasmic reticulum gateway to apoptosis by Bcl-X(L) modulation of the InsP3R. Nat. Cell Biol. 7, 1021–1028 (2005).
Huang, H. et al. An interaction between Bcl-xL and the voltage-dependent anion channel (VDAC) promotes mitochondrial Ca2+ uptake. J. Biol. Chem. 288, 19870–19881 (2013).
Eno, C. O. et al. Distinct roles of mitochondria- and ER-localized Bcl-xL in apoptosis resistance and Ca2+ homeostasis. Mol. Biol. Cell. 23, 2605–2618 (2012).
Rong, Y. & Distelhorst, C. W. Bcl-2 protein family members: versatile regulators of calcium signaling in cell survival and apoptosis. Annu. Rev. Physiol. 70, 73–91 (2008).
Durie, D. et al. HuR controls mitochondrial morphology through the regulation of Bcl translation. Translation (Austin). 1, e23980 (2013).
Lessene, G., Czabotar, P. E. & Colman, P. M. BCL-2 family antagonists for cancer therapy. Nat. Rev. Drug. Discov. 7, 989–1000 (2008).
Badrichani, A. Z. et al. Bcl-2 and Bcl-XL serve an anti-inflammatory function in endothelial cells through inhibition of NF-kappaB. J. Clin. Invest. 103, 543–553 (1999).
Choi, S. et al. Bcl-xL promotes metastasis independent of its anti-apoptotic activity. Nat. Commun. 7, 10384 (2016).
Carne Trecesson, S. et al. BCL-XL directly modulates RAS signalling to favour cancer cell stemness. Nat. Commun. 8, 1123 (2017).
Wang, C. & Youle, R. J. Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1’s inhibitory effect on Bak. Oncogene 31, 3177–3189 (2012).
Lindenboim, L. et al. Bak but not Bax is essential for Bcl-xS-induced apoptosis. Cell Death Differ. 12, 713–723 (2005).
Taylor, J. K. et al. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat. Biotechnol. 17, 1097–1100 (1999).
Sumantran, V. N. et al. Overexpression of Bcl-xS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res. 55, 2507–2510 (1995).
Hossini, A. M. et al. Conditional expression of exogenous Bcl-X(S) triggers apoptosis in human melanoma cells in vitro and delays growth of melanoma xenografts. FEBS Lett. 553, 250–256 (2003).
Kozopas, K. M. et al. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc. Natl Acad. Sci. USA 90, 3516–3520 (1993).
Reynolds, J. E. et al. Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer Res. 54, 6348–6352 (1994).
Bae, J. et al. MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J. Biol. Chem. 275, 25255–25261 (2000).
Kim, J. H., et al., MCL-1ES, a novel variant of MCL-1, associates with MCL-1L and induces mitochondrial cell death. FEBS letters. 2758–2764 (2009).
Day, C. L. et al. Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands. J. Biol. Chem. 280, 4738–4744 (2005).
Thomas, L. W., Lam, C. & Edwards, S. W. Mcl-1; the molecular regulation of protein function. FEBS Lett. 584, 2981–2989 (2010).
Morciano, G. et al. Mcl-1 involvement in mitochondrial dynamics is associated with apoptotic cell death. Mol. Biol. Cell. 27, 20–34 (2016).
Kim, J. H. & Bae, J. MCL-1ES induces MCL-1L-dependent BAX- and BAK-independent mitochondrial apoptosis. PLoS One 8, e79626 (2013).
Moore, M. J. et al. An alternative splicing network links cell-cycle control to apoptosis. Cell 142, 625–636 (2010).
Gao, Y. & Koide, K. Chemical perturbation of Mcl-1 pre-mRNA splicing to induce apoptosis in cancer cells. Acs. Chem. Biol. 8, 895–900 (2013).
Eckenrode, E. F. et al. Apoptosis protection by Mcl-1 and Bcl-2 modulation of inositol 1,4,5-trisphosphate receptor-dependent Ca2+ signaling. J. Biol. Chem. 285, 13678–13684 (2010).
Escudero, S. et al. Dynamic regulation of long-chain fatty acid oxidation by a noncanonical interaction between the MCL-1 BH3 Helix and VLCAD. Mol. Cell 69, 729–743 e7 (2018).
Seto, M. et al. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J. 7, 123–131 (1988).
Chen-Levy, Z., Nourse, J. & Cleary, M. L. The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. Mol. Cell. Biol. 9, 701–710 (1989).
Bissonnette, R. P. et al. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 359, 552–554 (1992).
Miyashita, T. & Reed, J. C. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 52, 5407–5411 (1992).
Katsumata, M. et al. Differential effects of Bcl-2 on T and B cells in transgenic mice. Proc. Natl. Acad. Sci. USA 89, 11376–11380 (1992).
Tsujimoto, Y. & Croce, C. M. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc. Natl Acad. Sci. USA 83, 5214–5218 (1986).
Peng, J. et al. The Bax BH3 peptide H2-H3 promotes apoptosis by inhibiting Bcl-2’s pore-forming and anti-Bax activities in the membrane. Sheng Wu Yi Xue Gong. Cheng Xue Za Zhi 26, 829–835 (2009).
Alnemri, E. et al. Overexpressed full-length human BCL2 extends the survival of baculovirus-infected Sf9 insect cells. Proc. Natl Acad. Sci. USA 16, 7295–7299 (1992).
Froesch, B. A. et al. Inhibition of p53 transcriptional activity by Bcl-2 requires its membrane-anchoring domain. J. Biol. Chem. 274, 6469–6475 (1999).
Massaad, C. A., Portier, B. P. & Taglialatela, G. Inhibition of transcription factor activity by nuclear compartment-associated Bcl-2. J. Biol. Chem. 279, 54470–54478 (2004).
Tanaka, S., Saito, K. & Reed, J. C. Structure-function analysis of the Bcl-2 oncoprotein. Addition of a heterologous transmembrane domain to portions of the Bcl-2 beta protein restores function as a regulator of cell survival. J. Biol. Chem. 268, 10920–10926 (1993).
Borner, C. et al. The protein bcl-2 alpha does not require membrane attachment, but two conserved domains to suppress apoptosis. J. Cell Biol. 126, 1059–1068 (1994).
Kawatani, M. et al. Transmembrane domain of Bcl-2 is required for inhibition of ceramide synthesis, but not cytochrome c release in the pathway of inostamycin-induced apoptosis. Exp. Cell Res. 286, 57–66 (2003).
Dremina, E. et al. Anti-apoptotic protein Bcl-2 interacts with and destabilizes the sarcoplasmic/endoplasmic reticulum Ca2+ -ATPase (SERCA). Biochem. J. 383(Pt 2), 361–370 (2004).
Liu, Y., Naumovski, L. & Hanawalt, P. Nucleotide excision repair capacity is attenuated in human promyelocytic HL60 cells that overexpress BCL2. Cancer Res. 57, 1650–1653 (1997).
Braun, F. et al. Protect and serve: Bcl-2 proteins as guardians and rulers of cancer cell survival. Cell Cycle 12, 2937–2947 (2013).
Decuypere, J. P., Parys, J. B. & Bultynck, G. Regulation of the autophagic bcl-2/beclin 1 interaction. Cells 1, 284–312 (2012).
Kuo, M. L. et al. Suppression of apoptosis by Bcl-2 to enhance benzene metabolites-induced oxidative DNA damage and mutagenesis: a possible mechanism of carcinogenesis. Mol. Pharmacol. 55, 894–901 (1999).
Hou, Y. et al. Bcl2 impedes DNA mismatch repair by directly regulating the hMSH2-hMSH6 heterodimeric complex. J. Biol. Chem. 282, 9279–9287 (2007).
Wang, Q. et al. Bcl2 negatively regulates DNA double-strand-break repair through a nonhomologous end-joining pathway. Mol. Cell 29, 488–498 (2008).
Beham, A. et al. Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene 15, 2767–2772 (1997).
Laulier, C. et al. Bcl-2 inhibits nuclear homologous recombination by localizing BRCA1 to the endomembranes. Cancer Res. 71, 3590–3602 (2011).
Laulier, C. & Lopez, B. S. The secret life of Bcl-2: apoptosis-independent inhibition of DNA repair by Bcl-2 family members. Mutat. Res. 751, 247–257 (2012).
Kagawa, S. et al. A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax. Gene Ther. 7, 75–79 (2000).
Bartholomeusz, G. A. et al. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood 109, 3470–3478 (2007).
Piche, A. et al. Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res. 58, 2134–2140 (1998).
Agarwala, S. S. et al. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur. J. Cancer 45, 1807–1814 (2009).
Schultz, J. et al. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res. 18, 549–557 (2008).
Wang, J. L. et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl Acad. Sci. USA 97, 7124–7129 (2000).
Yamaguchi, R. & Perkins, G. Mcl-1 levels need not be lowered for cells to be sensitized for ABT-263/737-induced apoptosis. Cell Death Dis. 2, e227 (2011).
Suryani, S. et al. Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts. Clin. Cancer Res. 20, 4520–4531 (2014).
Leverson, J. D. et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis. 6, e1590 (2015).
Besbes, S. & Billard, C. First MCL-1-selective BH3 mimetics as potential therapeutics for targeted treatment of cancer. Cell Death Dis. 6, e1810 (2015).
Kotschy, A. et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 538, 477–482 (2016).
Bauman, J. et al. Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res. 38, 8348–8356 (2010).
Shieh, J. J. et al. Modification of alternative splicing of Mcl-1 pre-mRNA using antisense morpholino oligonucleotides induces apoptosis in basal cell carcinoma cells. J. Invest. Dermatol. 129, 2497–2506 (2009).
Oltvai, Z. N., Milliman, C. L. & Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74, 609–619 (1993).
Schendel, S. L. et al. Channel formation by antiapoptotic protein Bcl-2. Proc. Natl Acad. Sci. USA 94, 5113–5118 (1997).
Wei, Y. et al. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol. Cell 30, 678–688 (2008).
Kirsch, D. G. et al. Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J. Biol. Chem. 274, 21155–21161 (1999).
Belka, C. & Budach, W. Anti-apoptotic Bcl-2 proteins: structure, function and relevance for radiation biology. Int. J. Radiat. Biol. 78, 643–658 (2002).
Reed, J. C. Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ. 13, 1378–1386 (2006).
Llambi, F. et al. BOK Is a Non-canonical BCL-2 Family Effector of Apoptosis Regulated by ER-Associated Degradation. Cell 165, 421–433 (2016).
Czabotar, P. E. et al. Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc. Natl. Acad. Sci. USA 104, 6217–6222 (2007).
Westphal, D. et al. Molecular biology of Bax and Bak activation and action. Biochim. Biophys. Acta 1813, 521–531 (2011).
Bingle, C. D. et al. Exon Skipping in Mcl-1 Results in a Bcl-2 Homology Domain 3 Only Gene Product That Promotes Cell Death. J. Biol. Chem. 275, 22136–22146 (2000).
Guillem, V., et al. BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia. Leuk Res. 1278–1284 (2015).
España, L. et al. Overexpression of Bcl-xL in Human Breast Cancer Cells Enhances Organ-Selective Lymph Node Metastasis. Breast Cancer Res. Treat. 87, 33–44 (2004).
Palve, V. et al. Overexpression of Mcl-1L splice variant is associated with poor prognosis and chemoresistance in oral cancers. PLoS One 9, e111927 (2014).
Gibson, L. et al. bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncogene 13, 665–675 (1996).
Noble, K. E. et al. Monocytes stimulate expression of the Bcl-2 family member, A1, in endothelial cells and confer protection against apoptosis. J. Immunol. 162, 1376–1383 (1999).
Choi, S. S. et al. A novel Bcl-2 related gene, Bfl-1, is overexpressed in stomach cancer and preferentially expressed in bone marrow. Oncogene 11, 1693–1698 (1995).
Ko, J. K. et al. Bfl-1S, a novel alternative splice variant of Bfl-1, localizes in the nucleus via its C-terminus and prevents cell death. Oncogene 22, 2457–2465 (2003).
Pattingre, S. et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122, 927–939 (2005).
Bharatham, N., Chi, S. W. & Yoon, H. S. Molecular basis of Bcl-X(L)-p53 interaction: insights from molecular dynamics simulations. PLoS One 6, e26014 (2011).
Jin, Z. et al. Bcl2 suppresses DNA repair by enhancing c-Myc transcriptional activity. J. Biol. Chem. 281, 14446–14456 (2006).
Zhao, J. et al. Bcl2 inhibits abasic site repair by down-regulating APE1 endonuclease activity. J. Biol. Chem. 283, 9925–9932 (2008).
Youn, C. K. et al. Bcl-2 expression suppresses mismatch repair activity through inhibition of E2F transcriptional activity. Nat. Cell Biol. 7, 137–147 (2005).
Kumar, T. S. et al. Anti-apoptotic protein BCL2 down-regulates DNA end joining in cancer cells. J. Biol. Chem. 285, 32657–32670 (2010).
Dutta, C. et al. BCL2 suppresses PARP1 function and nonapoptotic cell death. Cancer Res. 72, 4193–4203 (2012).
Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677–681 (2005).
Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421–3428 (2008).
Rudin, C. M. et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin. Cancer Res. 18, 3163–3169 (2012).
Gandhi, L. et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J. Clin. Oncol. 29, 909–916 (2011).
Wilson, W. H. et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 11, 1149–1159 (2010).
Roberts, A. W. et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 30, 488–496 (2012).
Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202–208 (2013).
Roberts, A. W. et al. Venetoclax in patients with previously treated chronic lymphocytic leukemia. Clin. Cancer Res. 23, 4527–4533 (2017).
Casara, P. et al. S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. Oncotarget 9, 20075–20088 (2018).
Lessene, G. et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat. Chem. Biol. 9, 390–397 (2013).
Merino, D. et al. Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. Sci Transl Med. 9, eaam7049 (2017).
Leverson, J. D. et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci. Transl. Med 7, 279ra40 (2015).
Punnoose, E. A. et al. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. Mol. Cancer Ther. 15, 1132–1144 (2016).
Leverson, J. D. et al. Found in translation: how preclinical research is guiding the clinical development of the BCL2-selective inhibitor venetoclax. Cancer Discov. 7, 1376–1393 (2017).
Phillips, D. C. et al. Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). BloodCancer J. 5, e368 (2015).
Li, Z., S. He, S. & Look, A.T. The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells. Leukemia. 33, 262–266 (2019).
Kuwana, T. et al. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 111, 331–342 (2002).
Vela, L. et al. Direct interaction of Bax and Bak proteins with Bcl-2 homology domain 3 (BH3)-only proteins in living cells revealed by fluorescence complementation. J. Biol. Chem. 288, 4935–4946 (2013).
Willis, S. N. et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315, 856–859 (2007).
Llambi, F. et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol. Cell 44, 517–531 (2011).
Letai, A. et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2, 183–192 (2002).
Leber, B., Lin, J. & Andrews, D. W. Embedded together: the life and death consequences of interaction of the Bcl-2 family with membranes. Apoptosis 12, 897–911 (2007).
Kale, J., Osterlund, E. J. & Andrews, D. W. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 25, 65–80 (2018).
Acknowledgements
CFAW was supported by the Hunter Melanoma Foundation Carol Foster Memorial Scholarship, MWB was supported by the University of Newcastle Priority Research Centre in Cancer Research, Innovation and Translation; NAB was supported by the Cancer Institute NSW (14CDF117) and the Hunter Medical Research Institute Vanessa McGuigan Memorial Fellowship in Ovarian Cancer.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Edited by P. Bouillet
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Warren, C.F.A., Wong-Brown, M.W. & Bowden, N.A. BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis 10, 177 (2019). https://doi.org/10.1038/s41419-019-1407-6
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41419-019-1407-6
- Springer Nature Limited
This article is cited by
-
CSPG4P12 polymorphism served as a susceptibility marker for esophageal cancer in Chinese population
BMC Cancer (2024)
-
The anti-inflammatory and anti-apoptotic effects of Achillea millefolium L. extracts on Clostridioides difficile ribotype 001 in human intestinal epithelial cells
BMC Complementary Medicine and Therapies (2024)
-
Emerging biomarkers and potential therapeutics of the BCL-2 protein family: the apoptotic and anti-apoptotic context
Egyptian Journal of Medical Human Genetics (2024)
-
New oxadiazole and pyrazoline derivatives as anti-proliferative agents targeting EGFR-TK: design, synthesis, biological evaluation and molecular docking study
Scientific Reports (2024)
-
Noxa inhibits oncogenesis through ZNF519 in gastric cancer and is suppressed by hsa-miR-200b-3p
Scientific Reports (2024)